News & Articles

A life-threatening mold infection known as health care-associated Fusarium solani meningitis can be associated with a delayed, but devastating, injury to the brainstem and its blood supply among those infected, according to physicians from UTHealth Houston.

 A medication that appeared to stabilize the function and shape of red blood cells in an earlier study for patients with sickle cell disease is now part of a Phase III clinical trial that is open for enrollment at UTHealth Houston.

After children experienced severe traumatic brain injury, the infusion of bone marrow mononuclear cells derived from the patient’s own bones led to less time spent in intensive care, less intense therapy, and, significantly, the structural preservation of white matter, which constitutes about half the total volume of the brain, according to new research from UTHealth Houston.

The body’s immune response to Epstein-Barr virus (EBV) may play a role in causing damage in people with multiple sclerosis, according to a new study led by UTHealth Houston.

The use of high-protease pancreatic replacement therapy demonstrated improvement in maladaptive behaviors, such as irritability, in preschool children with autism spectrum disorder (ASD), according to research conducted at 32 clinical sites, including UTHealth Houston.

Though still a third-year student with McGovern Medical School at UTHealth Houston, Gabriela Grangeiro Cruz is already working to broaden the medical field’s, and the public’s, understanding of Alzheimer’s disease by studying ways to prevent the neurocognitive disorder, which affects 6 million people living in the U.S.

Just as a song can remind us of the junior high dance or prom, sounds also have the ability to return traumatic memories. Pinpointing the location of these traumatic memories is the work behind a clinical trial, “Neuromodulation of the fear extinction circuit using temporally and anatomically specific TMS in humans,” led by Mohammed Milad, PhD, professor in the Louis A. Faillace Department of Psychiatry and Behavioral Sciences at McGovern Medical School at UTHealth Houston.

The Texas Therapeutics Institute at UTHealth Houston, led by Zhiqiang An, PhD, is expanding into the Texas Medical Center’s newly completed TMC3 Collaborative Building. The institute, part of The Brown Foundation Institute of Molecular Medicine for the Prevention of Human Diseases with McGovern Medical School at UTHealth Houston, focuses on antibody drug resistance mechanisms, biomarkers for therapeutic antibodies, and antibody drug discovery targeting human diseases.

Demetrios Stroubakis, 55, thought he was having a gallbladder attack when he arrived at the emergency room in August 2021 with jaundice. Instead, he was shocked to be diagnosed with pancreatic cancer.

A discovery of a mutation in the gene ACTA2 has given researchers, led by Dianna Milewicz, MD, PhD, with UTHealth Houston, insight into understanding the cause of a rare and progressive problem with arteries in the brain and a cause of strokes in young children, called moyamoya disease.